Document is current

Article History

Received: 11 February 2025

Accepted: 14 April 2025

First Online: 30 April 2025

Declarations

:

: This study was approved by the University of California San Francisco Institutional Review Board as part of a standing approval for chart review research on pediatric headache disorders (16–18622). The need for written informed consent was waived.

: Not applicable.

: Sara Pavitt is a site PI on a clinical trial investigating rimegepant as an acute treatment in pediatric patients migraine. She is a site SubI investigating ubrogepant as an acute treatment in pediatric patients with migraine. She receives no salary support from these trials. She is a site PI for PICORI funded REACH study in which she does receive salary support. Cynthia Morris – No disclosuresLauren Shin – No disclosuresAndrew Jones – No disclosuresBeata Vayngortin – No disclosuresNatalia Zorrilla – No disclosuresChengshi Jin – No disclosures Isabel Allen – No disclosuresAmy A. Gelfand: In the last 24 months, Dr. Gelfand has received royalties from UpToDate (for authorship), and honoraria from Elsevier (for authorship), the American Academy of Neurology (for editing) the Taiwan Headache Society (for speaking) and the Weill Cornell Neurology Department (for speaking). She receives a stipend from the American Headache Society for her role as Editor of Headache. She receives grant support from PCORI as a member of the Steering Committee for the REACH study and from the UCSF Resource Allocation Program as an investigator